The trastuzumab drug has shown "high efficacy" in curing early stage breast cancer and in some cases more advanced forms of the disease, the WHO said in a statement.
The World Health Organization (WHO) announced Wednesday that it had for the first time approved a “biosimilar” medicine — one derived from living sources rather than chemicals — to make breast cancer treatment affordable to women globally. The trastuzumab drug has shown “high efficacy” in curing early stage breast cancer and in some cases more advanced forms of the disease, the WHO said in a statement.
But the annual cost of the original drug is an average (of) USD 20,000, “a price that puts it out of reach of many women and healthcare systems in most countries,” the statement added. However, the biosimilar version of trastuzumab is generally 65 per cent cheaper than the original. “With this WHO listing, and more products expected in the prequalification pipeline, prices should decrease even further,” the WHO said.
The cheaper but equally effective biotherapeutic medicines are produced from biological sources such as cells rather than synthesised chemicals. They are usually manufactured by companies after the patent on the original product has expired. “WHO prequalification of biosimilar trastuzumab is good news for women everywhere,” said WHO director general Dr Tedros Adhanom Ghebreyesus.
“Women in many cultures suffer from gender disparity when it comes to accessing health services. In poor countries, there is the added burden of a lack of access to treatment for many, and the high cost of medicines. “Effective, affordable breast cancer treatment should be a right for all women, not the privilege of a few, ” he added. A few biosimilars of trastuzumab have come on the market in recent years, but none had previously been prequalified by WHO.
WHO prequalification gives countries the assurance that they are purchasing “quality health products”. “We need to act now and try to avoid more preventable deaths,” said Dr Mariangela Simao, WHO assistant director general for Medicines and Health Products. “The availability of biosimilars has decreased prices, making even innovative treatments more affordable and hopefully available to more people.”